The enzyme, poly(adenosine diphosphate-ribose) polymerase (PARP) crucially controls this pathway, making PARP inhibitors a promising treatment strategy for patients with breast cancer carrying BRCA1/2 pathogenic variants (9). Here, PARP1 is linked to breast cancer.